Knowledge

Across topics and issues, borders and industries, we have the thought leadership you need to stay ahead of changes in the law.

Across topics and issues, borders and industries, we have the thought leadership you need to stay ahead of changes in the law.

Follow us:

Publications

News

COVID-19: Daily Report for Life Sciences and Health Care Companies II

The Daily Report is a compilation of COVID-19 (coronavirus) news briefs from around the worldto helplife sciences and health care companies stay current in this challenging...

News

COVID-19: Daily Report for Life Sciences and Health Care Companies

The Daily Report is a compilation of COVID-19 (coronavirus) news briefs from around the worldto helplife sciences and health care companies stay current in this challenging...

News

COVID-19: Daily Report for Life Sciences and Health Care Companies

The Daily Report is a compilation of COVID-19 (coronavirus) news briefs from around the worldto helplife sciences and health care companies stay current in this challenging...

News

COVID-19: Daily Report for Life Sciences and Health Care Companies (23 - 27 March 2020)

The Daily Report is a compilation of COVID-19 (coronavirus) news briefs from around the worldto helplife sciences and health care companies stay current in this challenging...

News

FDA eases some postmarket adverse event reporting deadlines during COVID-19 pandemic
Registered Content

During the ongoing COVID-19 pandemic, the U.S. Food and Drug Administration (FDA) expects that workforces will be reduced at the same time that the use of medical products will increase....

News

COVID-19: Daily Report for Life Sciences and Health Care Companies

The Daily Report is a compilation of COVID-19 (coronavirus) news briefs from around the worldto helplife sciences and health care companies stay current in this challenging...

Hogan Lovells Publications

Talking the Cure: Discussing how the coronavirus pandemic is affecting the pharmaceutical industry and FDA Life Sciences and Health Care Podcast

In this episode, Phil Katz, David Horowitz, and Jim Johnson explore the impact on industry and FDA of the agency's decision to halt foreign inspections and take other steps that reduce...

Hogan Lovells Publications

Podcast: Talking the cure

Our team is always thinking about how to conquer and foresee the most significant industry issues facing our clients. Over the next year, we will touch on cutting edge topics such as...

Insights

“Misleading” to suggest a biosimilar is inferior, FDA draft guidance warns
Registered Content

As part of its continuing efforts to advance biologics competition, the U.S. Food and Drug Administration (FDA) on February 3 published a 10-page Q&A draft guidance, “Promotional...

Loading data